23 unchanged sentences
On April 9, 2026, we filed with the SEC a registration statement on Form S- 1 registering Clearthink's sale of the shares to be issued to Clearthink under the Purchase Agreement, which was declared effective by the SEC on April 15, 2026.
−Removed: On April 23, 2026, we initiated our first sale of shares to Clearthink, selling 350,000 shares and receiving $50,725 in gross proceeds.
+Added: From the April 15, 2026 commencement date through June 30, 2026, we sold 3,250,000 shares of our common stock to Clearthink and received $391,000 in gross and net proceeds.
+Added: Subsequent to June 30, 2026 through August 12, 2026, we have sold 3,000,000 shares of our common stock to Clearthink and received $323,000 in gross and net proceeds.
See the Exhibit Index for a list of exhibits filed as part of this report and incorporated herein by reference.
9 unchanged sentences
2018 Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company's annual report on Form S-8 filed on June 22, 2018)
−Removed: 2024 Equity Incentive Plan
+Added: 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.3 to the Company's quarterly report on Form 10-Q filed on May 15, 2026)
Revolving Line of Credit Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay (incorporated by reference to Exhibit 10.6 to the Company's annual report on Form 8-K filed on July 7, 2020)
38 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 14, 2026
BIOLARGO, INC.
1 unchanged sentence
Chief Executive Officer
+Added: August 14, 2026
/s/ CHARLES K.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.